Epigallocatechin-3-Gallate (EGCG) Improves Cognitive Deficits Aggravated by an Obesogenic Diet Through Modulation of Unfolded Protein Response in APPswe/PS1dE9 Mice
Miren Ettcheto(Universitat de Barcelona), Antoni Camins(Biomedical Research Networking Center on Neurodegenerative Diseases), Carme Auladell(Biomedical Research Networking Center on Neurodegenerative Diseases), Amanda Cano(Biomedical Research Networking Center on Neurodegenerative Diseases), Jaume Folch(Biomedical Research Networking Center on Neurodegenerative Diseases), Rubén D. Castro‐Torres(Universidad de Guadalajara), Ester Verdaguer(Biomedical Research Networking Center on Neurodegenerative Diseases), Carlos Beas‐Zárate(Universidad de Guadalajara), Jordi Olloquequi(University of Chile), Oriol Busquets(Biomedical Research Networking Center on Neurodegenerative Diseases), María L. García(Biomedical Research Networking Center on Neurodegenerative Diseases), Patrícia Regina Manzine(Universidade Federal de São Carlos)
Cited by 73
Related Papers
Metal-Based Nanoparticles as Antimicrobial Agents: An Overview
|Nanomaterials|2020|1.4k
Therapeutic potential of venom peptides
|Nature Reviews Drug Discovery|2003|786
Dual-drug loaded nanoparticles of Epigallocatechin-3-gallate (EGCG)/Ascorbic acid enhance therapeutic efficacy of EGCG in a APPswe/PS1dE9 Alzheimer's disease mice model
|Journal of Controlled Release|2019|330
Microemulsions and Nanoemulsions in Skin Drug Delivery
|Bioengineering|2022|291
Memantine loaded PLGA PEGylated nanoparticles for Alzheimer’s disease: in vitro and in vivo characterization
|Journal of Nanobiotechnology|2018|284